Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$21.35 -2.0%	$17.15	$13.40 ▼ $25.23	$3.57B	0.47	1.93 million shs	1.04 million shs
AKRO Akero Therapeutics	$53.92 +1.8%	$41.72	$17.86 ▼ $58.40	$4.30B	-0.12	991,887 shs	657,076 shs
AMYT Amryt Pharma	$14.70 +0.1%	$14.64	$6.41 ▼ $14.77	$940.21M	0.84	757,360 shs	2.39 million shs
PRGO Perrigo	$25.97 -1.1%	$26.03	$23.14 ▼ $30.93	$3.57B	0.45	1.50 million shs	677,523 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-0.96%	-1.14%	+43.79%	+23.62%	+40.91%
AKRO Akero Therapeutics	+2.67%	+16.92%	+17.97%	+21.34%	+175.70%
AMYT Amryt Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
PRGO Perrigo	-0.75%	-2.79%	+4.36%	-8.15%	-3.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.3038 of 5 stars	3.3	2.0	0.0	0.0	2.9	4.2	1.3
AKRO Akero Therapeutics	3.8709 of 5 stars	3.5	3.0	0.0	4.7	2.5	0.8	0.0
AMYT Amryt Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRGO Perrigo	4.9579 of 5 stars	3.1	5.0	4.2	3.5	2.6	2.5	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.60	Moderate Buy	$26.54	24.33% Upside
AKRO Akero Therapeutics	3.00	Buy	$82.50	53.01% Upside
AMYT Amryt Pharma	0.00	N/A	N/A	N/A
PRGO Perrigo	2.25	Hold	$33.00	27.05% Upside

Current Analyst Ratings Breakdown

Latest AMYT, PRGO, ACAD, and AKRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
5/27/2025	AKRO Akero Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$63.00 ➝ $64.00
5/21/2025	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00 ➝ $35.00
5/20/2025	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $24.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$28.00 ➝ $31.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$26.00 ➝ $26.00
5/19/2025	ACAD ACADIA Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$24.00 ➝ $28.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $30.00
5/19/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $32.00
5/16/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform

(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$996.28M	3.59	N/A	N/A	$2.63 per share	8.12
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$9.61 per share	N/A
AMYT Amryt Pharma	$222.54M	4.22	$0.98 per share	14.98	$5.58 per share	2.63
PRGO Perrigo	$4.34B	0.82	$5.42 per share	4.79	$35.19 per share	0.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	-$61.29M	$1.37	27.37	28.09	N/A	13.83%	25.83%	14.71%	8/5/2025 (Estimated)
AKRO Akero Therapeutics	-$151.76M	-$1.95	N/A	N/A	N/A	N/A	-32.46%	-29.83%	8/8/2025 (Estimated)
AMYT Amryt Pharma	$1M	-$0.06	N/A	735.00	N/A	-8.19%	1.70%	0.75%	N/A
PRGO Perrigo	-$12.70M	-$1.31	N/A	8.49	N/A	-3.64%	7.38%	3.18%	8/1/2025 (Estimated)

Latest AMYT, PRGO, ACAD, and AKRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/7/2025	Q1 2025	PRGO Perrigo	$0.56	$0.60	+$0.04	-$0.05	$1.09 billion	$1.04 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
AMYT Amryt Pharma	N/A	N/A	N/A	N/A	N/A
PRGO Perrigo	$1.16	4.47%	+4.77%	N/A	23 Years

Latest AMYT, PRGO, ACAD, and AKRO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/30/2025	PRGO Perrigo	quarterly	$0.29	4.55%	5/30/2025	5/30/2025	6/17/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.29	2.11
AKRO Akero Therapeutics	0.05	17.25	17.25
AMYT Amryt Pharma	0.64	1.57	0.94
PRGO Perrigo	0.94	2.56	1.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
AKRO Akero Therapeutics	N/A
AMYT Amryt Pharma	71.31%
PRGO Perrigo	95.91%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
AKRO Akero Therapeutics	7.94%
AMYT Amryt Pharma	5.66%
PRGO Perrigo	0.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	119.30 million	Optionable
AKRO Akero Therapeutics	30	79.72 million	64.26 million	Optionable
AMYT Amryt Pharma	2,020	63.96 million	60.34 million	Not Optionable
PRGO Perrigo	8,900	137.48 million	135.47 million	Optionable

AMYT, PRGO, ACAD, and AKRO Headlines

Recent News About These Companies

Perrigo Appoints New EVP of Global Operations

June 4 at 5:18 PM | tipranks.com

Perrigo Announces Global Operations and Supply Chain Leadership Transition

June 4 at 8:30 AM | prnewswire.com

California State Teachers Retirement System Acquires 14,893 Shares of Perrigo Company plc (NYSE:PRGO)

June 4 at 4:22 AM | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Takes $383,000 Position in Perrigo Company plc (NYSE:PRGO)

June 4 at 4:14 AM | marketbeat.com

Brokers Issue Forecasts for Perrigo FY2025 Earnings

June 3 at 1:33 AM | americanbankingnews.com

Perrigo Company plc (NYSE:PRGO) Shares Acquired by O Keefe Stevens Advisory Inc.

June 2 at 7:53 AM | marketbeat.com

Brokers Offer Predictions for Perrigo FY2025 Earnings

June 2 at 1:34 AM | marketbeat.com

Two Sigma Investments LP Has $2.89 Million Position in Perrigo Company plc (NYSE:PRGO)

June 1, 2025 | marketbeat.com

Nuveen Asset Management LLC Sells 292,474 Shares of Perrigo Company plc (NYSE:PRGO)

June 1, 2025 | marketbeat.com

Equities Analysts Offer Predictions for Perrigo Q2 Earnings

June 1, 2025 | americanbankingnews.com

Zacks Research Estimates Perrigo's Q2 Earnings (NYSE:PRGO)

May 31, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stake in Perrigo Company plc (NYSE:PRGO)

May 31, 2025 | marketbeat.com

Ex-Dividend Reminder: Brookfield Renewable Partners, Baxter International and Perrigo

May 29, 2025 | nasdaq.com

Twinbeech Capital LP Sells 28,734 Shares of Perrigo Company plc (NYSE:PRGO)

May 26, 2025 | marketbeat.com

Perrigo (NYSE:PRGO) Upgraded to Buy at Wall Street Zen

May 26, 2025 | americanbankingnews.com

Perrigo (NYSE:PRGO) Upgraded to "Buy" at Wall Street Zen

May 26, 2025 | marketbeat.com

Dividend Investors: Don't Be Too Quick To Buy Perrigo Company plc (NYSE:PRGO) For Its Upcoming Dividend

May 25, 2025 | finance.yahoo.com

18,102 Shares in Perrigo Company plc (NYSE:PRGO) Purchased by Nomura Holdings Inc.

May 24, 2025 | marketbeat.com

Perrigo to Attend the Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference

May 23, 2025 | prnewswire.com

Novem Group Invests $2.60 Million in Perrigo Company plc (NYSE:PRGO)

May 23, 2025 | marketbeat.com

iSAM Funds UK Ltd Invests $242,000 in Perrigo Company plc (NYSE:PRGO)

May 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMYT, PRGO, ACAD, and AKRO Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$21.34 -0.43 (-1.95%)

Closing price 03:59 PM Eastern

Extended Trading

$21.34 0.00 (0.00%)

As of 04:06 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Akero Therapeutics NASDAQ:AKRO

$53.92 +0.93 (+1.75%)

Closing price 03:59 PM Eastern

Extended Trading

$53.96 +0.04 (+0.08%)

As of 04:04 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Amryt Pharma NASDAQ:AMYT

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Perrigo NYSE:PRGO

$25.97 -0.29 (-1.09%)

Closing price 03:59 PM Eastern

Extended Trading

$25.97 0.00 (-0.02%)

As of 04:04 PM Eastern

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time